{"protocolSection":{"identificationModule":{"nctId":"NCT04537208","orgStudyIdInfo":{"id":"VAT00001"},"secondaryIdInfos":[{"id":"U1111-1250-4757","type":"OTHER","domain":"UTN"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older","officialTitle":"Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older"},"statusModule":{"statusVerifiedDate":"2023-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-09-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-11-19","type":"ACTUAL"},"completionDateStruct":{"date":"2021-11-19","type":"ACTUAL"},"studyFirstSubmitDate":"2020-09-02","studyFirstSubmitQcDate":"2020-09-02","studyFirstPostDateStruct":{"date":"2020-09-03","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-05-24","resultsFirstSubmitQcDate":"2023-05-24","resultsFirstPostDateStruct":{"date":"2023-06-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-15","lastUpdatePostDateStruct":{"date":"2025-09-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"},"collaborators":[{"name":"GlaxoSmithKline","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary objectives of the study were:\n\n* To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.\n* To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last injection.\n\nThe secondary objectives of the study are:\n\n* To describe binding antibody profile at Day 1, Day 22, Day 36, Day 181 (Cohort 1) or Day 202 (Cohort 2), and Day 366 (Cohort 1) or Day 387 (Cohort 2) of each study intervention group.\n* To describe the neutralizing antibody profile at Day 181 (Cohort 1) or Day 202 (Cohort 2) and at Day 366 (Cohort 1) and Day 387 (Cohort 2) of each study intervention group.\n* To describe the occurrence of virologically-confirmed coronavirus disease (COVID-19)-like illness and serologically-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\n* To evaluate the correlation / association between antibody responses to SARS-CoV-2 Recombinant Protein and the risk of virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.","detailedDescription":"The duration of each participant's participation in the study was approximately 365 days (Cohort 1) and 386 days (Cohort 2) post last injection."},"conditionsModule":{"conditions":["COVID-19 (Healthy Volunteers)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"This was a parallel group prevention study. Participants from 2 age groups (adults 18 through 49 years of age and adults 50 years of age and older) received either 1 injection (Cohort 1) or 2 injections (Cohort 2) of study vaccine or placebo control.\n\nAs a precautionary step, a sentinel safety cohort of 6 participants (younger adults only) within each dosing group from Cohort 1 was enrolled. An early safety data review was performed, including evaluation of safety data and laboratory measures to Day 9. Upon acceptable safety demonstrated from unblinded data review by limited members of the Sponsor Study Team, the remaining participants were enrolled simultaneously.","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Participants, outcome assessors, Investigators, laboratory personnel, and the majority of Sponsor study staff will be blinded to vaccine group assignment; injection schedule will be unblinded and those preparing/administering the study interventions will be unblinded.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":441,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1: Group 1: SARS-CoV-2 vaccine LD + AF03","type":"EXPERIMENTAL","description":"Participants received a single intramuscular (IM) injection of SARS-CoV2 vaccine low-dose (LD) formulation along with adjuvant AF03 on Day 1.","interventionNames":["Biological: CoV2 preS dTM-AF03 (low-dose)"]},{"label":"Cohort 1: Group 2: SARS-CoV-2 vaccine LD + AS03","type":"EXPERIMENTAL","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1.","interventionNames":["Biological: CoV2 preS dTM-AS03 (low-dose)"]},{"label":"Cohort 1: Group 3: SARS-CoV-2 vaccine HD + AF03","type":"EXPERIMENTAL","description":"Participants received a single IM injection of SARS-CoV2 vaccine high-dose (HD) formulation along with adjuvant AF03 on Day 1.","interventionNames":["Biological: CoV2 preS dTM-AF03 (high-dose)"]},{"label":"Cohort 1: Group 4: SARS-CoV-2 vaccine HD + AS03","type":"EXPERIMENTAL","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1.","interventionNames":["Biological: CoV2 preS dTM-AS03 (high-dose)"]},{"label":"Cohort 1: Group 5: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received an IM injection of placebo matching to SARS-CoV2 vaccine on Day 1.","interventionNames":["Biological: Placebo (0.9% normal saline)"]},{"label":"Cohort 2: Group 6: SARS-CoV-2 vaccine LD + AF03","type":"EXPERIMENTAL","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively.","interventionNames":["Biological: CoV2 preS dTM-AF03 (low-dose)"]},{"label":"Cohort 2: Group 7: SARS-CoV-2 vaccine LD + AS03","type":"EXPERIMENTAL","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively.","interventionNames":["Biological: CoV2 preS dTM-AS03 (low-dose)"]},{"label":"Cohort 2: Group 8: SARS-CoV-2 vaccine HD + AF03","type":"EXPERIMENTAL","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively.","interventionNames":["Biological: CoV2 preS dTM-AF03 (high-dose)"]},{"label":"Cohort 2: Group 9: SARS-CoV-2 vaccine HD + AS03","type":"EXPERIMENTAL","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively.","interventionNames":["Biological: CoV2 preS dTM-AS03 (high-dose)"]},{"label":"Cohort 2: Group 10: SARS-CoV-2 vaccine HD","type":"EXPERIMENTAL","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively.","interventionNames":["Biological: CoV2 preS dTM (high-dose) without adjuvant"]},{"label":"Cohort 2: Group 11: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received an IM injection of placebo matching to SARS-CoV2 on Day 1 and Day 22, respectively.","interventionNames":["Biological: Placebo (0.9% normal saline)"]}],"interventions":[{"type":"BIOLOGICAL","name":"CoV2 preS dTM-AF03 (low-dose)","description":"Pharmaceutical form: liquid; route of administration: intramuscular injection","armGroupLabels":["Cohort 1: Group 1: SARS-CoV-2 vaccine LD + AF03","Cohort 2: Group 6: SARS-CoV-2 vaccine LD + AF03"]},{"type":"BIOLOGICAL","name":"CoV2 preS dTM-AF03 (high-dose)","description":"Pharmaceutical form: liquid; route of administration: intramuscular injection","armGroupLabels":["Cohort 1: Group 3: SARS-CoV-2 vaccine HD + AF03","Cohort 2: Group 8: SARS-CoV-2 vaccine HD + AF03"]},{"type":"BIOLOGICAL","name":"CoV2 preS dTM-AS03 (low-dose)","description":"Pharmaceutical form: liquid; route of administration: intramuscular injection","armGroupLabels":["Cohort 1: Group 2: SARS-CoV-2 vaccine LD + AS03","Cohort 2: Group 7: SARS-CoV-2 vaccine LD + AS03"]},{"type":"BIOLOGICAL","name":"CoV2 preS dTM-AS03 (high-dose)","description":"Pharmaceutical form: liquid; route of administration: intramuscular injection","armGroupLabels":["Cohort 1: Group 4: SARS-CoV-2 vaccine HD + AS03","Cohort 2: Group 9: SARS-CoV-2 vaccine HD + AS03"]},{"type":"BIOLOGICAL","name":"CoV2 preS dTM (high-dose) without adjuvant","description":"Pharmaceutical form: liquid; route of administration: intramuscular injection","armGroupLabels":["Cohort 2: Group 10: SARS-CoV-2 vaccine HD"]},{"type":"BIOLOGICAL","name":"Placebo (0.9% normal saline)","description":"Pharmaceutical form: liquid; route of administration: intramuscular injection","armGroupLabels":["Cohort 1: Group 5: Placebo","Cohort 2: Group 11: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 1","description":"GMTs of SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.","timeFrame":"Day 1 (pre-vaccination)"},{"measure":"Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 22","description":"GMTs of SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.","timeFrame":"Day 22 (post-vaccination)"},{"measure":"Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 36","description":"GMTs of SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.","timeFrame":"Day 36 (post-vaccination)"},{"measure":"Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.","timeFrame":"Day 1 (pre-vaccination) and Day 22 (post-vaccination)"},{"measure":"Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.","timeFrame":"Day 1 (pre-vaccination) and Day 36 (post-vaccination)"},{"measure":"Number of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.","timeFrame":"Day 1 (pre-vaccination) and Day 22 (post-vaccination)"},{"measure":"Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.","timeFrame":"Day 1 (pre-vaccination) and Day 36 (post-vaccination)"},{"measure":"Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22","description":"Seroconversion was defined as participants with a Baseline (Day 1) titer value below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post vaccination (at Day 22). LLOQ of the neutralization assay was a titer of 10.","timeFrame":"Day 22 (post-vaccination)"},{"measure":"Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36","description":"Seroconversion was defined as participants with a Baseline (Day 1) titer value below LLOQ with a detectable neutralization antibody titer above assay LLOQ post vaccination (at Day 36). LLOQ of the neutralization assay was a titer of 10.","timeFrame":"Day 36 (post-vaccination)"},{"measure":"Number of Participants With Immediate Unsolicited Adverse Events (AEs)","description":"An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessary had to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions prelisted in the case report form (CRF) in terms of diagnosis and/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited systemic AEs occurred during that time were recorded as immediate unsolicited AEs in the CRF. Reported AEs for each arm were presented as pre-specified in the study protocol.","timeFrame":"Within 30 minutes post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])"},{"measure":"Number of Participants With Solicited Injection Site Reactions","description":"A solicited reaction (SR) was defined as an \"expected\" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF and considered as related to vaccination. Solicited injection site reactions included pain, erythema and swelling. Reported AEs for each arm were presented as pre-specified in the study protocol.","timeFrame":"Within 7 days post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])"},{"measure":"Number of Participants With Solicited Systemic Reactions","description":"An SR was defined as an \"expected\" AR (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise and myalgia. Reported AEs for each arm were presented as pre-specified in the study protocol.","timeFrame":"Within 7 days post any and each vaccination (Vaccination 1 [i.e., Day 1] and 2 [i.e., Day 22])"},{"measure":"Number of Participants With Unsolicited Adverse Events","description":"An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessary had to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol.","timeFrame":"Within 21 days post any and each vaccination (Vaccination 1 [i.e., Day 1] and 2 [i.e., Day 22])"},{"measure":"Number of Participants With Medically Attended Adverse Events (MAAE)","description":"A MAAE were AEs with a new onset or a worsening of a condition that prompted the participant to seek unplanned medical advice at a physician's office (including phone contact or email) or emergency department. An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessarily had to have a causal relationship with treatment. Reported AEs for each arm were presented as pre-specified in the study protocol.","timeFrame":"From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)"},{"measure":"Number of Participants With Serious Adverse Events (SAE)","description":"An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Reported AEs for each arm were presented as pre-specified in the study protocol.","timeFrame":"From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)"},{"measure":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. Reported AEs for each arm were presented as pre-specified in the study protocol.","timeFrame":"From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)"},{"measure":"Number of Participants With Laboratory Test Results Based on US FDA Toxicity Grading Guidance","description":"Laboratory tests included hemoglobin (male and female), above and below normal white blood cell, lymphocytes, neutrophils \\& eosinophils, platelet count, creatinine and blood urea nitrogen, hyponatremia \\& hypernatremia, hyperkalemia \\& hypokalemia, hyperglycemia (non-fasting), hypoproteinemia, alkaline phosphate, alanine aminotransferase, aspartate aminotransferase, bilirubin (with any increase in liver function test \\[LFT\\], bilirubin (normal in LFT), amylase \\& lipase, Urine: protein, glucose \\& blood. The US FDA Guidance for Industry \"Toxicity Grading Scale for Healthy Adults and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\" was used for grading. As per the guidance, Grade 1 = mild, Grade 2 = moderate and Grade 3 = severe.","timeFrame":"From Day 1 up to 8 days post last dose (i.e., up to Day 9 for Cohort 1 and up to Day 30 for Cohort 2)"}],"secondaryOutcomes":[{"measure":"Geometric Mean Concentration (GMC) of Anti-S Binding Antibody at Day 1, 22, 36, 181, 202, 366 and 387","description":"GMC of Anti-S binding antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) and were measured in binding antibody units/milliliter (BAU/mL).","timeFrame":"Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 181 (only for Cohort 1), Day 202 (only for Cohort 2), Day 366 (only for Cohort 1), and Day 387 (only for Cohort 2)"},{"measure":"Geometric Mean Fold-rise (GMFR) of Binding Antibody Concentration at Day 22, 36, 181, 202, 366 and 387","description":"Binding antibody titers were evaluated by ELISA. Fold-rise was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 01, Day 36/Day 01, Day 181/Day 1, Day 202/Day 1, Day 366/Day 1, and Day 387/Day 1.","timeFrame":"Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 181 (only for Cohort 1), Day 202 (only for Cohort 2), Day 366 (only for Cohort 1), and Day 387 (only for Cohort 2)"},{"measure":"Number of Participants With >=2-Fold and >=4- Fold Rise in Anti-S Binding Antibody Concentration at Day 22, 36, 181, 202, 366 and 387","description":"Binding Antibody Titers were evaluated by ELISA. Fold rise (2-fold and 4-fold) was calculated as the ratio of titer values for binding antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1 and Day 36/Day 1, Day 181/Day 1, Day 202/Day 1, Day 366/Day 1, and Day 387/Day 1.","timeFrame":"Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 181 (only for Cohort 1), Day 202 (only for Cohort 2), Day 366 (only for Cohort 1), and Day 387 (only for Cohort 2)"},{"measure":"Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 181, 202, 366 and 387","description":"GMTs of SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.","timeFrame":"Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387 (post-vaccination)"},{"measure":"Geometric Mean Fold-rise of Serum Neutralization Antibody Titer at Day 181, 202, 366 and 387","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., for Cohort 1: Day 181/Day 1 and Day 366/Day 1; Cohort 2: Day 202/Day 1 and Day 387/Day 1.","timeFrame":"Day 1 (pre-vaccination), Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387 (post-vaccination)"},{"measure":"Number of Participants With 2-Fold and 4-Fold Rise in Serum Neutralization Antibody Titer at Day 181, 202, 366 and 387","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Cohort 1: Day 181/Day 1 and Day 366/Day 1 and Cohort 2: Day 202/Day 1 and Day 387/Day 1.","timeFrame":"Day 1 (pre-vaccination), Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387 (post-vaccination)"},{"measure":"Percentage of Participants Achieving Seroconversion Against SARS-CoV2 Virus Antigens at Day 181, 202, 366 and 387","description":"Seroconversion was defined as participants with a Baseline (Day 1) titer value below LLOQ with a detectable neutralization antibody titer above assay LLOQ post vaccination (Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387). LLOQ of the neutralization assay was a titer of 10.","timeFrame":"Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387 (post-vaccination)"},{"measure":"Number of Participants With Virologically-confirmed Coronavirus Disease (COVID-19)-Like Illness","description":"Virologically-confirmed COVID-19-like illness was defined by specified clinical symptoms and signs and confirmed by positive result for SARS-CoV-2 by nucleic acid amplification test (NAAT) on a respiratory sample in association with a COVID-19-like illness. The various COVID-19-like illness symptoms were cough, fever, anosmia, ageusia, chillblains, difficulty breathing, shortness of breath, pneumonia, stroke, myocarditis, myocardial infarction, thromboembolic event, purpura fulminans, pharyngitis, chills, myalgia, headache, rhinorrhea, abdominal pain, nausea, diarrhea and vomiting.","timeFrame":"Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)"},{"measure":"Number of Participants With Serologically-confirmed SARS-CoV-2 Infection","description":"Serologically-confirmed SARS-CoV-2 infection was defined as a change from negative to positive result in serum for presence of antibodies specific to non-Spike protein of SARS-CoV-2 detected by ELISA assay from any post-baseline sampling time point compared to the Baseline value.","timeFrame":"Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)"},{"measure":"Correlates of Risk / Protection Based on Antibody Responses to SARS-CoV-2","description":"Correlate of risk / protection based on antibody responses to SARS-CoV-2 was evaluated using virus neutralization or ELISA, considering virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.","timeFrame":"From Day 1 up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 18 years of age or older on the day of inclusion.\n* Informed consent form had been signed and dated.\n* Able to attend all scheduled visits and complied with all study procedures.\n\nExclusion Criteria:\n\n* Participant was pregnant, or lactating, or of childbearing potential and not used an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination. To be considered of non-childbearing potential, a female was post-menopausal for at least 1 year or surgically sterile.\n* Receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines.\n* Prior administration of a coronavirus vaccine SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome).\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* History of SARS-CoV-2 infection, confirmed either clinically, serologically, or microbiologically\n* Chronic illness or condition considered to potentially increase the risk for severe COVID illness or that, in the opinion of the Investigator, was at a stage where it might interfere with study conduct or completion.\n* Receipt of any therapy known to had in-vitro antiviral activity against SARS-CoV-2 within 72 hours prior to the first blood drew.\n* Health care workers provided direct participant care for COVID-19 participants.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Sciences & Operations","affiliation":"Sanofi Pasteur, a Sanofi Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Investigational Site Number 8400004","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Investigational Site Number 8400012","city":"Rolling Hills Estates","state":"California","zip":"90274","country":"United States","geoPoint":{"lat":33.78779,"lon":-118.35813}},{"facility":"Investigational Site Number 8400011","city":"Hollywood","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Investigational Site Number 8400019","city":"Melbourne","state":"Florida","zip":"32934","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"facility":"Investigational Site Number 8400016","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Investigational Site Number 8400002","city":"Omaha","state":"Nebraska","zip":"68134","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Investigational Site Number 8400001","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Investigational Site Number 8400007","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Investigational Site Number 8400008","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Investigational Site Number 8400003","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Investigational Site Number 8400014","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}}]},"referencesModule":{"references":[{"pmid":"35035955","type":"DERIVED","citation":"De Rosa SC, Cohen KW, Bonaparte M, Fu B, Garg S, Gerard C, Goepfert PA, Huang Y, Larocque D, McElrath MJ, Morris D, Van der Most R, de Bruyn G, Pagnon A. Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate. Clin Transl Immunology. 2022 Jan 11;11(1):e1360. doi: 10.1002/cti2.1360. eCollection 2022."},{"pmid":"33887209","type":"DERIVED","citation":"Goepfert PA, Fu B, Chabanon AL, Bonaparte MI, Davis MG, Essink BJ, Frank I, Haney O, Janosczyk H, Keefer MC, Koutsoukos M, Kimmel MA, Masotti R, Savarino SJ, Schuerman L, Schwartz H, Sher LD, Smith J, Tavares-Da-Silva F, Gurunathan S, DiazGranados CA, de Bruyn G. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Lancet Infect Dis. 2021 Sep;21(9):1257-1270. doi: 10.1016/S1473-3099(21)00147-X. Epub 2021 Apr 19."}],"seeAlsoLinks":[{"label":"VAT00001 Plain Language Results Summary","url":"https://www.trialsummaries.com/Study/StudyDetails?id=25373&tenant=MT_SNY_9011"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 441 participants were enrolled, of which 439 were vaccinated in the study.","recruitmentDetails":"The study was conducted at 10 active sites in the United States between 03 September 2020 to 19 November 2021.","groups":[{"id":"FG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single intramuscular (IM) injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine low-dose (LD) formulation along with adjuvant AF03 on Day 1."},{"id":"FG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"FG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine high-dose (HD) formulation along with adjuvant AF03 on Day 1."},{"id":"FG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"FG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"FG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"FG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"FG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"FG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"FG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"FG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"34"},{"groupId":"FG002","numSubjects":"34"},{"groupId":"FG003","numSubjects":"34"},{"groupId":"FG004","numSubjects":"34"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"84"},{"groupId":"FG007","numSubjects":"27"},{"groupId":"FG008","numSubjects":"85"},{"groupId":"FG009","numSubjects":"18"},{"groupId":"FG010","numSubjects":"29"}]},{"type":"Vaccinated on Day 1","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"34"},{"groupId":"FG002","numSubjects":"34"},{"groupId":"FG003","numSubjects":"34"},{"groupId":"FG004","numSubjects":"34"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"82"},{"groupId":"FG007","numSubjects":"27"},{"groupId":"FG008","numSubjects":"85"},{"groupId":"FG009","numSubjects":"18"},{"groupId":"FG010","numSubjects":"29"}]},{"type":"Vaccinated on Day 22","comment":"Only Cohort 2 participants received second dose of vaccine at Day 22.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"26"},{"groupId":"FG006","numSubjects":"80"},{"groupId":"FG007","numSubjects":"26"},{"groupId":"FG008","numSubjects":"85"},{"groupId":"FG009","numSubjects":"17"},{"groupId":"FG010","numSubjects":"29"}]},{"type":"Safety Analysis Set (SafAS)","comment":"Participants who had received at least one injection of study intervention and were analyzed according to the study intervention they actually received.","achievements":[{"groupId":"FG000","comment":"2 participants randomized to 'Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03' received only one injection in Cohort 2 and thus included in arm 'Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03' for safety analysis.","numSubjects":"36"},{"groupId":"FG001","comment":"2 participants randomized to 'Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03' received only one injection in Cohort 2 and thus included in arm 'Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03' for safety analysis.","numSubjects":"36"},{"groupId":"FG002","comment":"1 participant randomized to 'Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03' received only one injection in Cohort 2 and thus included in arm 'Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03' for safety analysis.","numSubjects":"35"},{"groupId":"FG003","numSubjects":"34"},{"groupId":"FG004","numSubjects":"34"},{"groupId":"FG005","comment":"2 participants randomized to 'Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03' received only one injection in Cohort 2 and thus included in arm 'Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03' for safety analysis.","numSubjects":"26"},{"groupId":"FG006","comment":"2 participants randomized to 'Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03' received only one injection in Cohort 2 and thus included in arm 'Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03' for safety analysis.","numSubjects":"80"},{"groupId":"FG007","comment":"1 participant randomized to 'Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03' received only one injection in Cohort 2 and thus included in arm 'Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03' for safety analysis.","numSubjects":"26"},{"groupId":"FG008","numSubjects":"85"},{"groupId":"FG009","numSubjects":"18"},{"groupId":"FG010","numSubjects":"29"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"31"},{"groupId":"FG002","numSubjects":"28"},{"groupId":"FG003","numSubjects":"27"},{"groupId":"FG004","numSubjects":"26"},{"groupId":"FG005","numSubjects":"23"},{"groupId":"FG006","numSubjects":"71"},{"groupId":"FG007","numSubjects":"24"},{"groupId":"FG008","numSubjects":"69"},{"groupId":"FG009","numSubjects":"14"},{"groupId":"FG010","numSubjects":"21"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"16"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"8"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"Protocol deviation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"7"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"7"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis was performed on all randomized participants.","groups":[{"id":"BG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"BG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"BG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"BG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"BG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"BG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"BG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"BG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"BG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"BG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"BG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."},{"id":"BG011","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"34"},{"groupId":"BG004","value":"34"},{"groupId":"BG005","value":"28"},{"groupId":"BG006","value":"84"},{"groupId":"BG007","value":"27"},{"groupId":"BG008","value":"85"},{"groupId":"BG009","value":"18"},{"groupId":"BG010","value":"29"},{"groupId":"BG011","value":"441"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42.8","spread":"14.2"},{"groupId":"BG001","value":"41.9","spread":"12.8"},{"groupId":"BG002","value":"39.8","spread":"15.5"},{"groupId":"BG003","value":"39.0","spread":"17.2"},{"groupId":"BG004","value":"39.6","spread":"15.7"},{"groupId":"BG005","value":"43.7","spread":"14.1"},{"groupId":"BG006","value":"42.9","spread":"14.9"},{"groupId":"BG007","value":"42.2","spread":"15.5"},{"groupId":"BG008","value":"44.7","spread":"15.5"},{"groupId":"BG009","value":"34.8","spread":"10.2"},{"groupId":"BG010","value":"43.2","spread":"16.2"},{"groupId":"BG011","value":"42.1","spread":"15.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"36"},{"groupId":"BG007","value":"18"},{"groupId":"BG008","value":"44"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"14"},{"groupId":"BG011","value":"229"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"48"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"41"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"15"},{"groupId":"BG011","value":"212"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"3"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"28"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"15"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"72"},{"groupId":"BG007","value":"25"},{"groupId":"BG008","value":"78"},{"groupId":"BG009","value":"16"},{"groupId":"BG010","value":"26"},{"groupId":"BG011","value":"383"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"5"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 1","description":"GMTs of SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.","populationDescription":"Analysis was performed on Per-protocol analysis set for immunogenicity (PPAS-IAS) population which included all participants who received at least one injection of study intervention and had evaluable immunogenicity data, with no major protocol violations. Here, \"overall number of participants analyzed\" signifies participants with available data for this outcome measure (OM).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Day 1 (pre-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% confidence interval (CI) was not computable as the standard deviation (SD) of the sample was 0, since all participants had the same value."},{"groupId":"OG001","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG002","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG003","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG004","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG005","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG006","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG007","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG008","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG009","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG010","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 22","description":"GMTs of SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Day 22 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"68"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"69"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG001","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG002","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG003","value":"5.27","lowerLimit":"4.72","upperLimit":"5.89"},{"groupId":"OG004","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG005","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG006","value":"5.29","lowerLimit":"4.89","upperLimit":"5.73"},{"groupId":"OG007","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG008","value":"5.59","lowerLimit":"4.93","upperLimit":"6.34"},{"groupId":"OG009","value":"5.35","lowerLimit":"4.62","upperLimit":"6.19"},{"groupId":"OG010","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 36","description":"GMTs of SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Day 36 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"60"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"66"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG001","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG002","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG003","value":"5.31","lowerLimit":"4.69","upperLimit":"6.01"},{"groupId":"OG004","value":"5.17","lowerLimit":"4.83","upperLimit":"5.53"},{"groupId":"OG005","value":"11.5","lowerLimit":"6.17","upperLimit":"21.4"},{"groupId":"OG006","value":"17.4","lowerLimit":"12.1","upperLimit":"25.0"},{"groupId":"OG007","value":"31.2","lowerLimit":"16.4","upperLimit":"59.4"},{"groupId":"OG008","value":"69.0","lowerLimit":"48.3","upperLimit":"98.5"},{"groupId":"OG009","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG010","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Day 1 (pre-vaccination) and Day 22 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG001","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG002","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG003","value":"1.05","lowerLimit":"0.945","upperLimit":"1.18"},{"groupId":"OG004","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG005","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG006","value":"1.06","lowerLimit":"0.977","upperLimit":"1.15"},{"groupId":"OG007","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG008","value":"1.12","lowerLimit":"0.986","upperLimit":"1.27"},{"groupId":"OG009","value":"1.07","lowerLimit":"0.924","upperLimit":"1.24"},{"groupId":"OG010","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Day 1 (pre-vaccination) and Day 36 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG001","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG002","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG003","value":"1.06","lowerLimit":"0.938","upperLimit":"1.20"},{"groupId":"OG004","value":"1.03","lowerLimit":"0.966","upperLimit":"1.11"},{"groupId":"OG005","value":"2.42","lowerLimit":"1.26","upperLimit":"4.67"},{"groupId":"OG006","value":"3.36","lowerLimit":"2.33","upperLimit":"4.85"},{"groupId":"OG007","value":"6.24","lowerLimit":"3.27","upperLimit":"11.9"},{"groupId":"OG008","value":"14.0","lowerLimit":"9.78","upperLimit":"20.1"},{"groupId":"OG009","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG010","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"PRIMARY","title":"Number of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 1.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (pre-vaccination) and Day 22 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"classes":[{"title":">=2-fold rise","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}]}]},{"title":">=4-fold rise","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of neutralizing antibodies post-vaccination (on Day 36) and pre-vaccination (on Day 1) i.e., Day 36/Day 1.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (pre-vaccination) and Day 36 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"19"}]}],"classes":[{"title":">=2-fold rise","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"14"},{"groupId":"OG008","value":"57"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":">=4-fold rise","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"14"},{"groupId":"OG008","value":"49"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22","description":"Seroconversion was defined as participants with a Baseline (Day 1) titer value below lower limit of quantification (LLOQ) with a detectable neutralization antibody titer above assay LLOQ post vaccination (at Day 22). LLOQ of the neutralization assay was a titer of 10.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 22 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"14.2"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"16.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"16.8"},{"groupId":"OG003","value":"4.2","lowerLimit":"0.1","upperLimit":"21.1"},{"groupId":"OG004","value":"0","lowerLimit":"0","upperLimit":"13.7"},{"groupId":"OG005","value":"0","lowerLimit":"0","upperLimit":"19.5"},{"groupId":"OG006","value":"3.0","lowerLimit":"0.4","upperLimit":"10.4"},{"groupId":"OG007","value":"0","lowerLimit":"0","upperLimit":"15.4"},{"groupId":"OG008","value":"5.9","lowerLimit":"1.6","upperLimit":"14.4"},{"groupId":"OG009","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"},{"groupId":"OG010","value":"0","lowerLimit":"0","upperLimit":"15.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36","description":"Seroconversion was defined as participants with a Baseline (Day 1) titer value below LLOQ with a detectable neutralization antibody titer above assay LLOQ post vaccination (at Day 36). LLOQ of the neutralization assay was a titer of 10.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 36 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation (5 mcg) along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"15.4"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"16.1"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"17.6"},{"groupId":"OG003","value":"4.2","lowerLimit":"0.1","upperLimit":"21.1"},{"groupId":"OG004","value":"4.2","lowerLimit":"0.1","upperLimit":"21.1"},{"groupId":"OG005","value":"43.8","lowerLimit":"19.8","upperLimit":"70.1"},{"groupId":"OG006","value":"52.5","lowerLimit":"39.1","upperLimit":"65.7"},{"groupId":"OG007","value":"70.0","lowerLimit":"45.7","upperLimit":"88.1"},{"groupId":"OG008","value":"87.7","lowerLimit":"77.2","upperLimit":"94.5"},{"groupId":"OG009","value":"0","lowerLimit":"0","upperLimit":"28.5"},{"groupId":"OG010","value":"0","lowerLimit":"0","upperLimit":"17.6"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Immediate Unsolicited Adverse Events (AEs)","description":"An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessary had to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions prelisted in the case report form (CRF) in terms of diagnosis and/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited systemic AEs occurred during that time were recorded as immediate unsolicited AEs in the CRF. Reported AEs for each arm were presented as pre-specified in the study protocol.","populationDescription":"Analyzed on safety analysis set (SafAS) population which included randomized participants who had received at least one injection of study intervention and were analyzed according to study intervention they actually received. Here, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were evaluable for assessment for the specified Group, as there was only 1 vaccination administered to Cohort 1.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 30 minutes post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"classes":[{"title":"Post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Post vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Post vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Injection Site Reactions","description":"A solicited reaction (SR) was defined as an \"expected\" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF and considered as related to vaccination. Solicited injection site reactions included pain, erythema and swelling. Reported AEs for each arm were presented as pre-specified in the study protocol.","populationDescription":"Analysis was performed on SafAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM and 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were available for assessment for the specified Group, as there was only 1 vaccination administered to Cohort 1.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 7 days post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"classes":[{"title":"Pain post-any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"73"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"80"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"6"}]}]},{"title":"Pain post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"53"},{"groupId":"OG007","value":"13"},{"groupId":"OG008","value":"64"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"4"}]}]},{"title":"Pain post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"70"},{"groupId":"OG007","value":"19"},{"groupId":"OG008","value":"78"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"3"}]}]},{"title":"Erythema post-any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"19"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"39"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"}]}]},{"title":"Erythema post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Erythema post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"19"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"37"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"}]}]},{"title":"Swelling post-any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}]}]},{"title":"Swelling post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Swelling post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Reactions","description":"An SR was defined as an \"expected\" AR (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise and myalgia. Reported AEs for each arm were presented as pre-specified in the study protocol.","populationDescription":"Analysis was performed on SafAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM and 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were available for assessment for the specified Group, as there was only 1 vaccination administered to Cohort 1.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 7 days post any and each vaccination (Vaccination 1 [i.e., Day 1] and 2 [i.e., Day 22])","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"classes":[{"title":"Fever post-any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"25"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Fever post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Fever post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"16"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"23"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Headache post-any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"60"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"59"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"7"}]}]},{"title":"Headache post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"34"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"7"}]}]},{"title":"Headache post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"57"},{"groupId":"OG007","value":"16"},{"groupId":"OG008","value":"53"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"3"}]}]},{"title":"Malaise post-any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"61"},{"groupId":"OG007","value":"19"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"6"}]}]},{"title":"Malaise post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"24"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"5"}]}]},{"title":"Malaise post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"64"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"}]}]},{"title":"Myalgia post-any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"63"},{"groupId":"OG007","value":"19"},{"groupId":"OG008","value":"69"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"3"}]}]},{"title":"Myalgia post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"32"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"2"}]}]},{"title":"Myalgia post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"60"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"3"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Adverse Events","description":"An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessary had to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol.","populationDescription":"Analysis was performed on SafAS population. Here, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were available for assessment for the specified Group, as there was only 1 vaccination administered to Cohort 1.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 21 days post any and each vaccination (Vaccination 1 [i.e., Day 1] and 2 [i.e., Day 22])","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"classes":[{"title":"Post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"50"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"9"}]}]},{"title":"Post vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"7"}]}]},{"title":"Post vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"29"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"39"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"3"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Medically Attended Adverse Events (MAAE)","description":"A MAAE were AEs with a new onset or a worsening of a condition that prompted the participant to seek unplanned medical advice at a physician's office (including phone contact or email) or emergency department. An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessarily had to have a causal relationship with treatment. Reported AEs for each arm were presented as pre-specified in the study protocol.","populationDescription":"Analysis was performed on SafAS population.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAE)","description":"An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Reported AEs for each arm were presented as pre-specified in the study protocol.","populationDescription":"Analysis was performed on SafAS population.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively"},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. Reported AEs for each arm were presented as pre-specified in the study protocol.","populationDescription":"Analysis was performed on SafAS population.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"80"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Laboratory Test Results Based on US FDA Toxicity Grading Guidance","description":"Laboratory tests included hemoglobin (male and female), above and below normal white blood cell, lymphocytes, neutrophils \\& eosinophils, platelet count, creatinine and blood urea nitrogen, hyponatremia \\& hypernatremia, hyperkalemia \\& hypokalemia, hyperglycemia (non-fasting), hypoproteinemia, alkaline phosphate, alanine aminotransferase, aspartate aminotransferase, bilirubin (with any increase in liver function test \\[LFT\\], bilirubin (normal in LFT), amylase \\& lipase, Urine: protein, glucose \\& blood. The US FDA Guidance for Industry \"Toxicity Grading Scale for Healthy Adults and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\" was used for grading. As per the guidance, Grade 1 = mild, Grade 2 = moderate and Grade 3 = severe.","populationDescription":"Analysis was performed on SafAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM and 'number analyzed' = participants with available data for each specified category. Reported data for each arm were presented as pre-specified in the study protocol.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to 8 days post last dose (i.e., up to Day 9 for Cohort 1 and up to Day 30 for Cohort 2)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"classes":[{"title":"Hemoglobin: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"4"}]}]},{"title":"Hemoglobin: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hemoglobin: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hemoglobin (Female): Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"16"},{"groupId":"OG008","value":"44"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"}]}]},{"title":"Hemoglobin (Female): Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"16"},{"groupId":"OG008","value":"44"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hemoglobin (Female): Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"16"},{"groupId":"OG008","value":"44"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hemoglobin (Male): Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"44"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"41"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"}]}]},{"title":"Hemoglobin (Male): Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"44"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"41"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hemoglobin (Male): Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"44"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"41"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Above normal white blood cell: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Above normal white blood cell: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Above normal white blood cell: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Below normal white blood cell: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"}]}]},{"title":"Below normal white blood cell: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Below normal white blood cell: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Absolute Lymphocytes Decreased: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Absolute Lymphocytes Decreased: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Absolute Lymphocytes Decreased: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Absolute Neutrophils Decreased: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"}]}]},{"title":"Absolute Neutrophils Decreased: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Absolute Neutrophils Decreased: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Absolute Eosinophils: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Absolute Eosinophils: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Absolute Eosinophils: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"84"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Platelets Decreased: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Platelets Decreased: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"}]}]},{"title":"Platelets Decreased: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"}]}]},{"title":"Creatinine: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"}]}]},{"title":"Creatinine: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Creatinine: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Blood Urea Nitrogen: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Blood Urea Nitrogen: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"}]}]},{"title":"Blood Urea Nitrogen: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hyponatremia: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hyponatremia: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hyponatremia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hypernatremia: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hypernatremia: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hypernatremia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hyperkalemia: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"77"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hyperkalemia: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"77"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hyperkalemia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"77"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hypokalemia: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"77"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hypokalemia: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"77"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hypokalemia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"77"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hyperglycemia: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"31"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"71"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"78"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"2"}]}]},{"title":"Hyperglycemia: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"31"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"71"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"78"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"2"}]}]},{"title":"Hyperglycemia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"31"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"71"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"78"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hypoproteinemia: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"}]}]},{"title":"Hypoproteinemia: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Hypoproteinemia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Alkaline phosphate: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Alkaline phosphate: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Alkaline phosphate: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Alanine aminotransferase: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"2"}]}]},{"title":"Alanine aminotransferase: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Alanine aminotransferase: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Aspartate aminotransferase: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"}]}]},{"title":"Aspartate aminotransferase: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Aspartate aminotransferase: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Bilirubin - with any increase in LFT: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Bilirubin - with any increase in LFT: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Bilirubin - with any increase in LFT: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Bilirubin - with normal in LFT: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Bilirubin - with normal in LFT: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"}]}]},{"title":"Bilirubin - with normal in LFT: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Amylase: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"}]}]},{"title":"Amylase: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"}]}]},{"title":"Amylase: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Lipase: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"}]}]},{"title":"Lipase: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"}]}]},{"title":"Lipase: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Urine - protein: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"2"}]}]},{"title":"Urine - protein: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Urine - protein: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Urine - glucose: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Urine - glucose: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Urine - glucose: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"85"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Urine - blood: Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"19"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Urine - blood: Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"19"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Urine - blood: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"19"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) of Anti-S Binding Antibody at Day 1, 22, 36, 181, 202, 366 and 387","description":"GMC of Anti-S binding antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) and were measured in binding antibody units/milliliter (BAU/mL).","populationDescription":"Analysis was performed on PPAS-IAS population. Here, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were evaluable for assessment in the specified Group for the specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"BAU/mL","timeFrame":"Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 181 (only for Cohort 1), Day 202 (only for Cohort 2), Day 366 (only for Cohort 1), and Day 387 (only for Cohort 2)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"68"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"69"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG001","value":"9.80","lowerLimit":"9.08","upperLimit":"10.6"},{"groupId":"OG002","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG003","value":"10.1","lowerLimit":"8.76","upperLimit":"11.8"},{"groupId":"OG004","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG005","value":"11.7","lowerLimit":"8.56","upperLimit":"15.9"},{"groupId":"OG006","value":"9.66","lowerLimit":"9.25","upperLimit":"10.1"},{"groupId":"OG007","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG008","value":"9.73","lowerLimit":"9.18","upperLimit":"10.3"},{"groupId":"OG009","value":"10.5","lowerLimit":"8.34","upperLimit":"13.3"},{"groupId":"OG010","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]},{"title":"Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"68"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"69"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","lowerLimit":"18.8","upperLimit":"63.8"},{"groupId":"OG001","value":"61.8","lowerLimit":"35.8","upperLimit":"107"},{"groupId":"OG002","value":"46.1","lowerLimit":"24.8","upperLimit":"86.0"},{"groupId":"OG003","value":"160","lowerLimit":"78.4","upperLimit":"327"},{"groupId":"OG004","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG005","value":"45.2","lowerLimit":"21.0","upperLimit":"97.0"},{"groupId":"OG006","value":"88.4","lowerLimit":"60.6","upperLimit":"129"},{"groupId":"OG007","value":"50.2","lowerLimit":"28.6","upperLimit":"88.4"},{"groupId":"OG008","value":"136","lowerLimit":"101","upperLimit":"184"},{"groupId":"OG009","value":"10.4","lowerLimit":"8.44","upperLimit":"12.8"},{"groupId":"OG010","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]},{"title":"Day 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"60"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"66"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","lowerLimit":"13.9","upperLimit":"48.8"},{"groupId":"OG001","value":"73.7","lowerLimit":"43.2","upperLimit":"126"},{"groupId":"OG002","value":"41.0","lowerLimit":"22.2","upperLimit":"75.5"},{"groupId":"OG003","value":"136","lowerLimit":"70.2","upperLimit":"264"},{"groupId":"OG004","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG005","value":"1049","lowerLimit":"448","upperLimit":"2457"},{"groupId":"OG006","value":"3571","lowerLimit":"2597","upperLimit":"4910"},{"groupId":"OG007","value":"3086","lowerLimit":"1781","upperLimit":"5346"},{"groupId":"OG008","value":"7842","lowerLimit":"6120","upperLimit":"10049"},{"groupId":"OG009","value":"29.8","lowerLimit":"15.4","upperLimit":"57.4"},{"groupId":"OG010","value":"9.45","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]},{"title":"Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","lowerLimit":"15.0","upperLimit":"172"},{"groupId":"OG001","value":"145","lowerLimit":"27.8","upperLimit":"757"},{"groupId":"OG002","value":"21.7","lowerLimit":"11.2","upperLimit":"42.2"},{"groupId":"OG003","value":"127","lowerLimit":"21.1","upperLimit":"765"},{"groupId":"OG004","value":"44.6","lowerLimit":"9.75","upperLimit":"204"}]}]},{"title":"Day 202","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"925","lowerLimit":"2.78","upperLimit":"307000"},{"groupId":"OG006","value":"828","lowerLimit":"344","upperLimit":"1993"},{"groupId":"OG007","value":"1338","lowerLimit":"154","upperLimit":"11655"},{"groupId":"OG008","value":"3451","lowerLimit":"1439","upperLimit":"8275"},{"groupId":"OG009","value":"28070","lowerLimit":"7802","upperLimit":"101000"},{"groupId":"OG010","value":"217","lowerLimit":"4.01","upperLimit":"11732"}]}]},{"title":"Day 366","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2161","lowerLimit":"92.8","upperLimit":"50304"},{"groupId":"OG001","value":"7355","lowerLimit":"221","upperLimit":"245000"},{"groupId":"OG002","value":"1250","lowerLimit":"126","upperLimit":"12379"},{"groupId":"OG003","value":"12580","lowerLimit":"2121","upperLimit":"74606"},{"groupId":"OG004","value":"6265","lowerLimit":"361","upperLimit":"109000"}]}]},{"title":"Day 387","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"3439","lowerLimit":"0","upperLimit":"1000000"},{"groupId":"OG006","value":"9009","lowerLimit":"738","upperLimit":"110000"},{"groupId":"OG007","value":"24115","lowerLimit":"10016","upperLimit":"58060"},{"groupId":"OG008","value":"37532","lowerLimit":"13416","upperLimit":"105000"},{"groupId":"OG009","value":"4114","lowerLimit":"0.641","upperLimit":"26400000"},{"groupId":"OG010","value":"1126","lowerLimit":"NA","upperLimit":"NA","comment":"95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold-rise (GMFR) of Binding Antibody Concentration at Day 22, 36, 181, 202, 366 and 387","description":"Binding antibody titers were evaluated by ELISA. Fold-rise was calculated as the ratio of geometric mean concentrations of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 01, Day 36/Day 01, Day 181/Day 1, Day 202/Day 1, Day 366/Day 1, and Day 387/Day 1.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were evaluable for assessment in the specified Group for the specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 181 (only for Cohort 1), Day 202 (only for Cohort 2), Day 366 (only for Cohort 1), and Day 387 (only for Cohort 2)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"classes":[{"title":"Day 22/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.67","lowerLimit":"1.99","upperLimit":"6.76"},{"groupId":"OG001","value":"6.30","lowerLimit":"3.69","upperLimit":"10.8"},{"groupId":"OG002","value":"4.88","lowerLimit":"2.62","upperLimit":"9.10"},{"groupId":"OG003","value":"15.8","lowerLimit":"8.08","upperLimit":"30.8"},{"groupId":"OG004","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG005","value":"3.67","lowerLimit":"1.85","upperLimit":"7.28"},{"groupId":"OG006","value":"9.12","lowerLimit":"6.24","upperLimit":"13.3"},{"groupId":"OG007","value":"5.32","lowerLimit":"3.02","upperLimit":"9.36"},{"groupId":"OG008","value":"13.8","lowerLimit":"10.2","upperLimit":"18.7"},{"groupId":"OG009","value":"0.989","lowerLimit":"0.966","upperLimit":"1.01"},{"groupId":"OG010","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]},{"title":"Day 36/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.75","lowerLimit":"1.47","upperLimit":"5.16"},{"groupId":"OG001","value":"7.52","lowerLimit":"4.45","upperLimit":"12.7"},{"groupId":"OG002","value":"4.34","lowerLimit":"2.35","upperLimit":"7.99"},{"groupId":"OG003","value":"13.4","lowerLimit":"7.18","upperLimit":"25.1"},{"groupId":"OG004","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG005","value":"91.0","lowerLimit":"36.6","upperLimit":"226"},{"groupId":"OG006","value":"367","lowerLimit":"267","upperLimit":"504"},{"groupId":"OG007","value":"327","lowerLimit":"188","upperLimit":"566"},{"groupId":"OG008","value":"812","lowerLimit":"621","upperLimit":"1061"},{"groupId":"OG009","value":"2.78","lowerLimit":"1.34","upperLimit":"5.75"},{"groupId":"OG010","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]},{"title":"Day 181/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.39","lowerLimit":"1.59","upperLimit":"18.2"},{"groupId":"OG001","value":"14.5","lowerLimit":"2.76","upperLimit":"76.3"},{"groupId":"OG002","value":"2.30","lowerLimit":"1.18","upperLimit":"4.47"},{"groupId":"OG003","value":"13.4","lowerLimit":"2.23","upperLimit":"80.9"},{"groupId":"OG004","value":"4.72","lowerLimit":"1.03","upperLimit":"21.6"}]}]},{"title":"Day 202/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"58.2","lowerLimit":"0.910","upperLimit":"3722"},{"groupId":"OG006","value":"68.9","lowerLimit":"30.3","upperLimit":"156"},{"groupId":"OG007","value":"142","lowerLimit":"16.2","upperLimit":"1233"},{"groupId":"OG008","value":"387","lowerLimit":"157","upperLimit":"954"},{"groupId":"OG009","value":"2970","lowerLimit":"826","upperLimit":"10687"},{"groupId":"OG010","value":"23.0","lowerLimit":"0.424","upperLimit":"1241"}]}]},{"title":"Day 366/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"229","lowerLimit":"9.82","upperLimit":"5323"},{"groupId":"OG001","value":"685","lowerLimit":"21.0","upperLimit":"22298"},{"groupId":"OG002","value":"132","lowerLimit":"13.4","upperLimit":"1310"},{"groupId":"OG003","value":"1331","lowerLimit":"224","upperLimit":"7895"},{"groupId":"OG004","value":"663","lowerLimit":"38.2","upperLimit":"11509"}]}]},{"title":"Day 387/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"364","lowerLimit":"0","upperLimit":"1000000"},{"groupId":"OG006","value":"933","lowerLimit":"53.9","upperLimit":"16147"},{"groupId":"OG007","value":"2552","lowerLimit":"1060","upperLimit":"6144"},{"groupId":"OG008","value":"3972","lowerLimit":"1420","upperLimit":"11111"},{"groupId":"OG009","value":"435","lowerLimit":"0.068","upperLimit":"2800000"},{"groupId":"OG010","value":"119","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With >=2-Fold and >=4- Fold Rise in Anti-S Binding Antibody Concentration at Day 22, 36, 181, 202, 366 and 387","description":"Binding Antibody Titers were evaluated by ELISA. Fold rise (2-fold and 4-fold) was calculated as the ratio of titer values for binding antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Day 22/Day 1 and Day 36/Day 1, Day 181/Day 1, Day 202/Day 1, Day 366/Day 1, and Day 387/Day 1.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were evaluable for assessment in the specified Group for the specified time point.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (pre-vaccination); Day 22 (post-vaccination), Day 36 (post-vaccination), Day 181 (only for Cohort 1), Day 202 (only for Cohort 2), Day 366 (only for Cohort 1), and Day 387 (only for Cohort 2)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"classes":[{"title":"Day 22/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"66"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Day 22/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"67"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"68"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"46"},{"groupId":"OG007","value":"13"},{"groupId":"OG008","value":"56"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"title":"Day 36/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"0"}]}]},{"title":"Day 36/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"58"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"65"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"0"}]}]},{"title":"Day 181/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"4"}]}]},{"title":"Day 181/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"}]}]},{"title":"Day 202/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"3"}]}]},{"title":"Day 202/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"3"}]}]},{"title":"Day 366/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"6"}]}]},{"title":"Day 366/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"6"}]}]},{"title":"Day 387/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}]},{"title":"Day 387/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 181, 202, 366 and 387","description":"GMTs of SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Titers were expressed in terms of 1/dilution.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were evaluable for assessment in the specified Group for the specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"classes":[{"title":"Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.89","lowerLimit":"3.91","upperLimit":"12.2"},{"groupId":"OG001","value":"8.81","lowerLimit":"3.74","upperLimit":"20.7"},{"groupId":"OG002","value":"5.00","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG003","value":"9.99","lowerLimit":"3.62","upperLimit":"27.5"},{"groupId":"OG004","value":"10.9","lowerLimit":"4.73","upperLimit":"25.3"}]}]},{"title":"Day 202","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"31.7","lowerLimit":"0.089","upperLimit":"11282"},{"groupId":"OG006","value":"14.5","lowerLimit":"6.47","upperLimit":"32.4"},{"groupId":"OG007","value":"30.8","lowerLimit":"3.50","upperLimit":"271"},{"groupId":"OG008","value":"53.6","lowerLimit":"21.3","upperLimit":"135"},{"groupId":"OG009","value":"355","lowerLimit":"84.7","upperLimit":"1486"},{"groupId":"OG010","value":"16.0","lowerLimit":"2.18","upperLimit":"117"}]}]},{"title":"Day 366","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","lowerLimit":"6.67","upperLimit":"190"},{"groupId":"OG001","value":"159","lowerLimit":"21.2","upperLimit":"1199"},{"groupId":"OG002","value":"36.3","lowerLimit":"3.51","upperLimit":"376"},{"groupId":"OG003","value":"127","lowerLimit":"29.3","upperLimit":"551"},{"groupId":"OG004","value":"242","lowerLimit":"33.4","upperLimit":"1761"}]}]},{"title":"Day 387","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"30.1","lowerLimit":"0","upperLimit":"240000000000"},{"groupId":"OG006","value":"235","lowerLimit":"28.8","upperLimit":"1913"},{"groupId":"OG007","value":"727","lowerLimit":"361","upperLimit":"1465"},{"groupId":"OG008","value":"1043","lowerLimit":"324","upperLimit":"3355"},{"groupId":"OG009","value":"39.7","lowerLimit":"0.006","upperLimit":"245000"},{"groupId":"OG010","value":"23.0","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold-rise of Serum Neutralization Antibody Titer at Day 181, 202, 366 and 387","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. Fold-rise was calculated as the ratio of titer values of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., for Cohort 1: Day 181/Day 1 and Day 366/Day 1; Cohort 2: Day 202/Day 1 and Day 387/Day 1.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were evaluable for assessment in the specified Group for the specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Day 1 (pre-vaccination), Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"classes":[{"title":"Day 181/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","lowerLimit":"0.781","upperLimit":"2.43"},{"groupId":"OG001","value":"1.76","lowerLimit":"0.748","upperLimit":"4.15"},{"groupId":"OG002","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."},{"groupId":"OG003","value":"2.00","lowerLimit":"0.724","upperLimit":"5.51"},{"groupId":"OG004","value":"2.19","lowerLimit":"0.947","upperLimit":"5.05"}]}]},{"title":"Day 202/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"6.34","lowerLimit":"0.018","upperLimit":"2256"},{"groupId":"OG006","value":"2.38","lowerLimit":"1.15","upperLimit":"4.91"},{"groupId":"OG007","value":"6.16","lowerLimit":"0.699","upperLimit":"54.3"},{"groupId":"OG008","value":"11.7","lowerLimit":"4.59","upperLimit":"30.1"},{"groupId":"OG009","value":"71.0","lowerLimit":"16.9","upperLimit":"297"},{"groupId":"OG010","value":"3.20","lowerLimit":"0.436","upperLimit":"23.5"}]}]},{"title":"Day 366/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.12","lowerLimit":"1.33","upperLimit":"38.0"},{"groupId":"OG001","value":"31.9","lowerLimit":"4.23","upperLimit":"240"},{"groupId":"OG002","value":"7.26","lowerLimit":"0.701","upperLimit":"75.2"},{"groupId":"OG003","value":"25.4","lowerLimit":"5.86","upperLimit":"110"},{"groupId":"OG004","value":"48.5","lowerLimit":"6.67","upperLimit":"352"}]}]},{"title":"Day 387/Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"6.02","lowerLimit":"0","upperLimit":"1000000"},{"groupId":"OG006","value":"49.5","lowerLimit":"4.55","upperLimit":"539"},{"groupId":"OG007","value":"145","lowerLimit":"72.2","upperLimit":"293"},{"groupId":"OG008","value":"209","lowerLimit":"64.8","upperLimit":"671"},{"groupId":"OG009","value":"7.95","lowerLimit":"0.001","upperLimit":"49046"},{"groupId":"OG010","value":"4.60","lowerLimit":"NA","upperLimit":"NA","comment":"NA Explanation: 95% CI was not computable as the SD of the sample was 0, since all participants had the same value."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With 2-Fold and 4-Fold Rise in Serum Neutralization Antibody Titer at Day 181, 202, 366 and 387","description":"SARS-CoV-2 neutralizing antibodies was measured using a neutralization assay. The fold rise (2-fold and 4-fold) was calculated as the ratio of titer values of antibodies post-vaccination at specified timepoints and pre-vaccination (on Day 1) i.e., Cohort 1: Day 181/Day 1 and Day 366/Day 1 and Cohort 2: Day 202/Day 1 and Day 387/Day 1.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were evaluable for assessment in the specified Group for the specified time point.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (pre-vaccination), Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"classes":[{"title":"Day 181/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"}]}]},{"title":"Day 202/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"19"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"2"}]}]},{"title":"Day 181/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}]},{"title":"Day 202/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"14"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"2"}]}]},{"title":"Day 366/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"}]}]},{"title":"Day 387/Day 1: >=2-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}]},{"title":"Day 366/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"}]}]},{"title":"Day 387/Day 1: >=4-fold rise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Seroconversion Against SARS-CoV2 Virus Antigens at Day 181, 202, 366 and 387","description":"Seroconversion was defined as participants with a Baseline (Day 1) titer value below LLOQ with a detectable neutralization antibody titer above assay LLOQ post vaccination (Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387). LLOQ of the neutralization assay was a titer of 10.","populationDescription":"Analysis was performed on PPAS-IAS population. Here, \"overall number of participants analyzed\" signifies participants with available data for this OM, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that none of the participants were evaluable for assessment in the specified Group for the specified time point.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Cohort 1: Day 181 and Day 366 and Cohort 2: Day 202 and Day 387 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"classes":[{"title":"Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"1.7","upperLimit":"40.5"},{"groupId":"OG001","value":"14.3","lowerLimit":"1.8","upperLimit":"42.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"28.5"},{"groupId":"OG003","value":"13.3","lowerLimit":"1.7","upperLimit":"40.5"},{"groupId":"OG004","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"}]}]},{"title":"Day 202","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG006","value":"24.0","lowerLimit":"9.4","upperLimit":"45.1"},{"groupId":"OG007","value":"37.5","lowerLimit":"8.5","upperLimit":"75.5"},{"groupId":"OG008","value":"73.1","lowerLimit":"52.2","upperLimit":"88.4"},{"groupId":"OG009","value":"100","lowerLimit":"39.8","upperLimit":"100"},{"groupId":"OG010","value":"40.0","lowerLimit":"5.3","upperLimit":"85.3"}]}]},{"title":"Day 366","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"28.4","upperLimit":"99.5"},{"groupId":"OG001","value":"83.3","lowerLimit":"35.9","upperLimit":"99.6"},{"groupId":"OG002","value":"50.0","lowerLimit":"11.8","upperLimit":"88.2"},{"groupId":"OG003","value":"85.7","lowerLimit":"42.1","upperLimit":"99.6"},{"groupId":"OG004","value":"85.7","lowerLimit":"42.1","upperLimit":"99.6"}]}]},{"title":"Day 387","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"50.0","lowerLimit":"1.3","upperLimit":"98.7"},{"groupId":"OG006","value":"77.8","lowerLimit":"40.0","upperLimit":"97.2"},{"groupId":"OG007","value":"100","lowerLimit":"54.1","upperLimit":"100"},{"groupId":"OG008","value":"100","lowerLimit":"69.2","upperLimit":"100"},{"groupId":"OG009","value":"100","lowerLimit":"15.8","upperLimit":"100"},{"groupId":"OG010","value":"100","lowerLimit":"2.5","upperLimit":"100"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologically-confirmed Coronavirus Disease (COVID-19)-Like Illness","description":"Virologically-confirmed COVID-19-like illness was defined by specified clinical symptoms and signs and confirmed by positive result for SARS-CoV-2 by nucleic acid amplification test (NAAT) on a respiratory sample in association with a COVID-19-like illness. The various COVID-19-like illness symptoms were cough, fever, anosmia, ageusia, chillblains, difficulty breathing, shortness of breath, pneumonia, stroke, myocarditis, myocardial infarction, thromboembolic event, purpura fulminans, pharyngitis, chills, myalgia, headache, rhinorrhea, abdominal pain, nausea, diarrhea and vomiting.","populationDescription":"Data for this OM (virologically confirmed COVID-19 like illness) was not collected and analyzed because of the limited number of COVID-19 cases before receiving an authorized/approved COVID-19 vaccine, and thus the corresponding anti-nucleoprotein testing was not conducted, and the planned efficacy analysis was not performed.","reportingStatus":"POSTED","timeFrame":"Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation (5 mcg) along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"type":"SECONDARY","title":"Number of Participants With Serologically-confirmed SARS-CoV-2 Infection","description":"Serologically-confirmed SARS-CoV-2 infection was defined as a change from negative to positive result in serum for presence of antibodies specific to non-Spike protein of SARS-CoV-2 detected by ELISA assay from any post-baseline sampling time point compared to the Baseline value.","populationDescription":"Data for this OM (serologically confirmed SARS-CoV2 infection) was not collected and analyzed because of the limited number of COVID-19 cases before receiving an authorized/approved COVID-19 vaccine, and thus the corresponding anti-nucleoprotein testing was not conducted, and the planned efficacy analysis was not performed.","reportingStatus":"POSTED","timeFrame":"Cohort 1: up to Day 366 (post-vaccination) and Cohort 2: up to Day 387 (post-vaccination)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]},{"type":"SECONDARY","title":"Correlates of Risk / Protection Based on Antibody Responses to SARS-CoV-2","description":"Correlate of risk / protection based on antibody responses to SARS-CoV-2 was evaluated using virus neutralization or ELISA, considering virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.","populationDescription":"Data for this OM (Correlates of Risk / Protection Based on Antibody Responses to SARS-CoV-2) was not collected and analyzed because of the limited number of COVID-19 cases before receiving an authorized/approved COVID-19 vaccine, and thus the corresponding anti-nucleoprotein testing was not conducted, and the planned efficacy analysis was not performed.","reportingStatus":"POSTED","timeFrame":"From Day 1 up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2","groups":[{"id":"OG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1."},{"id":"OG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1."},{"id":"OG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1."},{"id":"OG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1."},{"id":"OG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively."},{"id":"OG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively."},{"id":"OG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively."},{"id":"OG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Unsolicited AE: from Day 0 (pre-vaccination) up to 21 days post any vaccination. Solicited reactions: collected within 7 days post any vaccination. SAE data were collected from Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)","description":"SR: defined as an \"expected\" AR (sign or symptom) observed and reported under conditions prelisted (i.e., solicited) in protocol and CRF and considered as related to vaccination. Unsolicited AE: an observed AE that did not fulfill conditions of solicited reactions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. SafAS population. In AE section, solicited reaction Fever was reported as Pyrexia. Reported AEs for each arm were presented as pre-specified in protocol.","eventGroups":[{"id":"EG000","title":"Cohort 1: Group 1: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":36,"seriousNumAffected":2,"seriousNumAtRisk":36,"otherNumAffected":22,"otherNumAtRisk":36},{"id":"EG001","title":"Cohort 1: Group 2: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":36,"seriousNumAffected":1,"seriousNumAtRisk":36,"otherNumAffected":31,"otherNumAtRisk":36},{"id":"EG002","title":"Cohort 1: Group 3: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":35,"seriousNumAffected":1,"seriousNumAtRisk":35,"otherNumAffected":23,"otherNumAtRisk":35},{"id":"EG003","title":"Cohort 1: Group 4: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":34,"seriousNumAffected":0,"seriousNumAtRisk":34,"otherNumAffected":31,"otherNumAtRisk":34},{"id":"EG004","title":"Cohort 1: Group 5: Placebo","description":"Participants received a single IM injection of placebo matching to SARS-CoV2 vaccine on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":34,"seriousNumAffected":0,"seriousNumAtRisk":34,"otherNumAffected":15,"otherNumAtRisk":34},{"id":"EG005","title":"Cohort 2: Group 6: SARS-CoV-2 Vaccine LD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively.","deathsNumAffected":0,"deathsNumAtRisk":26,"seriousNumAffected":1,"seriousNumAtRisk":26,"otherNumAffected":21,"otherNumAtRisk":26},{"id":"EG006","title":"Cohort 2: Group 7: SARS-CoV-2 Vaccine LD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively.","deathsNumAffected":0,"deathsNumAtRisk":80,"seriousNumAffected":1,"seriousNumAtRisk":80,"otherNumAffected":75,"otherNumAtRisk":80},{"id":"EG007","title":"Cohort 2: Group 8: SARS-CoV-2 Vaccine HD + AF03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively.","deathsNumAffected":0,"deathsNumAtRisk":26,"seriousNumAffected":0,"seriousNumAtRisk":26,"otherNumAffected":25,"otherNumAtRisk":26},{"id":"EG008","title":"Cohort 2: Group 9: SARS-CoV-2 Vaccine HD + AS03","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively.","deathsNumAffected":0,"deathsNumAtRisk":85,"seriousNumAffected":2,"seriousNumAtRisk":85,"otherNumAffected":84,"otherNumAtRisk":85},{"id":"EG009","title":"Cohort 2: Group 10: SARS-CoV-2 Vaccine HD","description":"Participants received IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":10,"otherNumAtRisk":18},{"id":"EG010","title":"Cohort 2: Group 11: Placebo","description":"Participants received IM injection of placebo matching to SARS-CoV2 vaccine on Day 1 and Day 22, respectively.","deathsNumAffected":0,"deathsNumAtRisk":29,"seriousNumAffected":0,"seriousNumAtRisk":29,"otherNumAffected":14,"otherNumAtRisk":29}],"seriousEvents":[{"term":"Nipple Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Pelvic Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Craniocerebral Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Femoral Neck Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Breast Cancer Recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Intraductal Proliferative Breast Lesion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Abortion Missed","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]}],"otherEvents":[{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG008","numEvents":9,"numAffected":9,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":36},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG006","numEvents":7,"numAffected":6,"numAtRisk":80},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG008","numEvents":8,"numAffected":7,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Chest Discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG006","numEvents":14,"numAffected":13,"numAtRisk":80},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG008","numEvents":11,"numAffected":10,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Injection Site Discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Injection Site Erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG006","numEvents":20,"numAffected":19,"numAtRisk":80},{"groupId":"EG007","numEvents":5,"numAffected":4,"numAtRisk":26},{"groupId":"EG008","numEvents":41,"numAffected":39,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Injection Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":36},{"groupId":"EG001","numEvents":30,"numAffected":30,"numAtRisk":36},{"groupId":"EG002","numEvents":21,"numAffected":21,"numAtRisk":35},{"groupId":"EG003","numEvents":28,"numAffected":28,"numAtRisk":34},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":34},{"groupId":"EG005","numEvents":35,"numAffected":19,"numAtRisk":26},{"groupId":"EG006","numEvents":123,"numAffected":73,"numAtRisk":80},{"groupId":"EG007","numEvents":32,"numAffected":20,"numAtRisk":26},{"groupId":"EG008","numEvents":142,"numAffected":80,"numAtRisk":85},{"groupId":"EG009","numEvents":4,"numAffected":4,"numAtRisk":18},{"groupId":"EG010","numEvents":7,"numAffected":6,"numAtRisk":29}]},{"term":"Injection Site Pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":80},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG008","numEvents":18,"numAffected":16,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Injection Site Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG006","numEvents":16,"numAffected":16,"numAtRisk":80},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":26},{"groupId":"EG008","numEvents":31,"numAffected":27,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Malaise event which occurred 7 days post-vaccination was considered as an unsolicited AE.","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":36},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":36},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":35},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":34},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":34},{"groupId":"EG005","numEvents":17,"numAffected":15,"numAtRisk":26},{"groupId":"EG006","numEvents":75,"numAffected":61,"numAtRisk":80},{"groupId":"EG007","numEvents":24,"numAffected":19,"numAtRisk":26},{"groupId":"EG008","numEvents":88,"numAffected":68,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":8,"numAffected":6,"numAtRisk":29}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":5,"numAffected":4,"numAtRisk":26},{"groupId":"EG006","numEvents":30,"numAffected":28,"numAtRisk":80},{"groupId":"EG007","numEvents":8,"numAffected":7,"numAtRisk":26},{"groupId":"EG008","numEvents":25,"numAffected":25,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Blood Potassium Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Blood Urea Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":2,"numAffected":1,"numAtRisk":80},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Myalgia events which occurred 7 days post-vaccination was considered as an unsolicited AE.","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":36},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":36},{"groupId":"EG002","numEvents":13,"numAffected":13,"numAtRisk":35},{"groupId":"EG003","numEvents":16,"numAffected":16,"numAtRisk":34},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":34},{"groupId":"EG005","numEvents":18,"numAffected":16,"numAtRisk":26},{"groupId":"EG006","numEvents":85,"numAffected":63,"numAtRisk":80},{"groupId":"EG007","numEvents":28,"numAffected":19,"numAtRisk":26},{"groupId":"EG008","numEvents":98,"numAffected":69,"numAtRisk":85},{"groupId":"EG009","numEvents":4,"numAffected":3,"numAtRisk":18},{"groupId":"EG010","numEvents":5,"numAffected":3,"numAtRisk":29}]},{"term":"Pain In Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Ageusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Anosmia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Headache events which occurred 7 days post-vaccination was considered as an unsolicited AE.","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":36},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":36},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":35},{"groupId":"EG003","numEvents":12,"numAffected":11,"numAtRisk":34},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":34},{"groupId":"EG005","numEvents":18,"numAffected":14,"numAtRisk":26},{"groupId":"EG006","numEvents":81,"numAffected":60,"numAtRisk":80},{"groupId":"EG007","numEvents":26,"numAffected":18,"numAtRisk":26},{"groupId":"EG008","numEvents":91,"numAffected":61,"numAtRisk":85},{"groupId":"EG009","numEvents":10,"numAffected":6,"numAtRisk":18},{"groupId":"EG010","numEvents":11,"numAffected":7,"numAtRisk":29}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Nasal Congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":29}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Due to the limited number of COVID-19 cases before receiving an authorized/approved COVID-19 vaccine, the corresponding anti-nucleoprotein testing was not conducted, the planned few efficacy outcome measures data were not collected and analysis was not performed."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."},"pointOfContact":{"title":"Trial Transparency Team","organization":"Sanofi Pasteur","email":"Contact-US@sanofi.com","phone":"800-633-1610","phoneExt":"6#"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-02-05","uploadDate":"2023-05-24T02:43","filename":"Prot_000.pdf","size":1065143},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-08-18","uploadDate":"2023-05-23T10:32","filename":"SAP_001.pdf","size":21467861}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D000086382","term":"COVID-19"}],"ancestors":[{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018352","term":"Coronavirus Infections"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000277","term":"Adjuvants, Pharmaceutic"},{"id":"D000077330","term":"Saline Solution"}],"ancestors":[{"id":"D010592","term":"Pharmaceutic Aids"},{"id":"D004364","term":"Pharmaceutical Preparations"},{"id":"D020313","term":"Specialty Uses of Chemicals"},{"id":"D020164","term":"Chemical Actions and Uses"},{"id":"D000077324","term":"Crystalloid Solutions"},{"id":"D007552","term":"Isotonic Solutions"},{"id":"D012996","term":"Solutions"}]}},"hasResults":true}